TRANSDERMAL CANCER ANTIGEN PEPTIDE PREPARATION

The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formu...

Full description

Saved in:
Bibliographic Details
Main Authors TANAKA, Masayasu, SAITO, Koichi, SUGINOBE, Natsuko, MAEDA, Hiroo, YAMAMOTO, Kazumitsu
Format Patent
LanguageEnglish
Published 03.03.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formula (1): R1-O-R2 (1), wherein R1 is a hydrocarbon group having 8-24 carbon atoms, and R2 is a group represented by the formula (2):or a group represented by the formula (3): -(CH2CH2O)mH (3), wherein m is an integer of 1-18.
Bibliography:Application Number: US202117529046